Product logins

Find logins to all Clarivate products below.


Psoriasis | Treatment Algorithms: Claims Data Analysis | Pediatric Psoriasis | US | 2020

Psoriasis is a chronic, inflammatory autoimmune skin disease that can affect children, adolescents, and adults. Given the limited number of therapies approved for pediatric psoriasis, treatment of this population is very challenging. Topical corticosteroids are associated with more-frequent and more-severe adverse events in children, and only two biologics, Amgen’s Enbrel and Janssen’s Stelara, are approved for pediatric and adolescent psoriasis patients, respectively. Topical corticosteroids continue to dominate in terms of patient share among targeted therapies; biologics, although used in later lines of therapy, are experiencing an increase in patient share, reflecting physicians’ growing acceptance of biological therapy use. The use of conventional systemics appears to be declining, underscoring a growing need for treatments with more-acceptable safety profiles.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed pediatric psoriasis patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric psoriasis patients?
  •  How have biologics such as Cosentyx, Enbrel, Humira, Stelara, Taltz, and Tremfya been integrated into the treatment algorithm?
  • What percentage of pediatric psoriasis patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  •  What percentage of pediatric psoriasis patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
  •  What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Related Market Assessment Reports

Report
Psoriasis | Access and Reimbursement | EU | 2019
MARKET OUTLOOK The treatment landscape for psoriasis in the top 5 European markets (France, Germany, Italy, Spain, UK) is extremely dynamic. Humira (AbbVie), Enbrel (Amgen), Stelara (Janssen),…
Report
Migraine | Special Topics | Spotlight on New Treatments in Migraine (US) | 2021
Since 2018, seven novel drugs have entered the U.S. market for the acute or preventive treatment of migraine, and at least four more are on the short-term horizon. Understanding how prescribers…
Report
Gout – Current Treatment – Treatment Algorithms: Claims Data Analysis – Gout (US)
Gout, a form of inflammatory arthritis, arises due to the persistent elevation of serum uric acid (sUA) levels. The condition manifests through sudden and intense gout flares, causing significant…
Report
Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)
Scleroderma (systemic sclerosis) (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Geographic Focus: China – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – China In-Depth (China)
The NHL therapy market in China is poised for significant growth over the next decade, driven by the introduction of novel therapies and the continued uptake and label expansion of premium-priced…